Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
Lisa-Maria Schanza, Maximilian Seles, Michael Stotz, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2495-2495
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway
Qiong Chen, Tao Liu, Yi Bao, et al.
Cancer Letters (2019) Vol. 469, pp. 68-77
Closed Access | Times Cited: 165
Tumor pH and metastasis: a malignant process beyond hypoxia
Oliver Thews, Anne Riemann
Cancer and Metastasis Reviews (2019) Vol. 38, Iss. 1-2, pp. 113-129
Closed Access | Times Cited: 162
Research progress in tumor angiogenesis and drug resistance in breast cancer
Jiancheng Mou, Chenhong Li, Qinghui Zheng, et al.
Cancer Biology and Medicine (2024), pp. 1-15
Open Access | Times Cited: 18
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
Christiane Klec, Felix Prinz, Martin Pichler
Molecular Oncology (2018) Vol. 13, Iss. 1, pp. 46-60
Open Access | Times Cited: 141
Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes
Э. А. Брага, М. В. Фридман, В. И. Логинов, et al.
Frontiers in Genetics (2019) Vol. 10
Open Access | Times Cited: 77
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer
Liyun Yong, Shasha Tang, Haixin Yu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 45
Hypoxia-mediated drug resistance in breast cancers
Courtney E. McAleese, Chandra Choudhury, Neville J. Butcher, et al.
Cancer Letters (2020) Vol. 502, pp. 189-199
Closed Access | Times Cited: 68
Extracellular vesicles transmitted miR‐31‐5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma
Jinlan He, Jianxiong He, Li Min, et al.
International Journal of Cancer (2019) Vol. 146, Iss. 4, pp. 1052-1063
Open Access | Times Cited: 64
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
Antonella Argentiero, Antonio Giovanni Solimando, Markus Krebs, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 5, pp. 1594-1594
Open Access | Times Cited: 61
A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3396-3396
Open Access | Times Cited: 52
Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer
Manuel Regouc, Gazanfer Belge, Anja Lorch, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 749-749
Open Access | Times Cited: 49
Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer
Dominik A. Barth, Felix Prinz, Julia Teppan, et al.
Non-Coding RNA (2020) Vol. 6, Iss. 3, pp. 27-27
Open Access | Times Cited: 49
MicroRNA‐99a‐5p suppresses breast cancer progression and cell‐cycle pathway through downregulating CDC25A
Hongzhen Qin, Wenfei Liu
Journal of Cellular Physiology (2018) Vol. 234, Iss. 4, pp. 3526-3537
Closed Access | Times Cited: 44
Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention
Christiane Klec, Tony Gutschner, Katrin Panzitt, et al.
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 3, pp. 177-186
Closed Access | Times Cited: 37
Potential New Therapeutic Approaches for Renal Cell Carcinoma
David C.H. Yang, Ching‐Hsien Chen
Seminars in Nephrology (2020) Vol. 40, Iss. 1, pp. 86-97
Open Access | Times Cited: 37
A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR‐567/ PRDX3 axis in renal cell carcinoma
Rui Yu, Jie Yao, Yu Ren
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 17, pp. 10177-10188
Open Access | Times Cited: 36
Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers
Dominik A. Barth, Rareş Drulă, Leonie Ott, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 30
Investigating the association of VHL gene variants with disease risk and clinicopathological outcomes in ccRCC patients from West Bengal, India
Srilagna Chatterjee, Nirvika Paul, Anwesha Das, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Closed Access
Role of miR‐486‐5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF‐β–activated kinase 1
Yanfa He, Jianzhen Liu, Yongjun Wang, et al.
Journal of Cellular Biochemistry (2018) Vol. 120, Iss. 3, pp. 2954-2963
Closed Access | Times Cited: 28
TGF‑β1 affects the renal cancer miRNome and regulates tumor cells proliferation
Karolina Hanusek, Beata Rybicka, Piotr Popławski, et al.
International Journal of Molecular Medicine (2022) Vol. 49, Iss. 4
Open Access | Times Cited: 15
Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study
Jian Deng, ShengYuan Tu, Lin Li, et al.
Cancer Reports (2024) Vol. 7, Iss. 6
Open Access | Times Cited: 3
Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
Xiaoran Ma, Jibiao Wu, Bin Wang, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 5
Open Access | Times Cited: 13
Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy
Youcef M. Rustum, Ryan J. Reis, Tara M. Rustum
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 902-902
Open Access | Times Cited: 7
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
Youcef M. Rustum, Sreenivasulu Chintala, Farukh A. Durrani, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3378-3378
Open Access | Times Cited: 23
Expression of miR‑146a‑5p in breast cancer and its role in proliferation of breast cancer cells
wei gao, Jing Hua, Jia Zhaoyang, et al.
Oncology Letters (2018)
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top